(5- fluoro- 2- methyl- 1- (4- pyridyl)methylene- 3- (N- benzyl)- indene)- acetamide hydrochloride

10/01/2002 - "Preclinical studies revealed good oral bioavailability and no toxicity in dogs and rats at single doses up to 500 mg/kg. In a Phase I trial, 21 patients with a range of solid tumors and good performance status received CP-461 p.o. "
02/01/2012 - "OSI-461 is a pro-apoptotic compound that has been proposed as a novel therapeutic option for patients suffering from solid tumors like prostate or colorectal carcinoma. "
02/01/2011 - "A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone."
02/01/2009 - "A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state."
10/01/2002 - "Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer."

10/01/2004 - "In the present study, we examined the combined effects of acyclic retinoid plus OSI-461 in the HepG2 human hepatoma cell line. "
10/01/2004 - "Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells."
10/01/2004 - "Our results suggest that the combination of acyclic retinoid plus OSI-461 might be an effective regimen for the chemoprevention and chemotherapy of human hepatoma and possibly other malignancies."

06/01/2004 - "By October 2002, Cell Pathways had selected hormone-refractory prostate cancer as the lead cancer indication for clinical development of OSI-461."
02/01/2011 - "The response rate seen in patients with prostate cancer was comparable to response rates seen in trials of mitoxantrone and prednisone alone, and further studies of the combination of OSI-461 and mitoxantrone were not pursued."

06/01/2004 - "In August 2001, OSI-461 entered phase II trials involving patients with chronic lymphocytic leukemia. "

06/01/2004 - "In July 2002, the company embarked on a pilot phase II study evaluating OSI-461 for the treatment of Crohn's disease. "